What is the catalog number for Mosapride?

The catalog number for Mosapride is HY-B0189.

What sizes are available for Mosapride?

Mosapride is available in the following size(s): 5 mg, 10 mM - 1 mL, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does Mosapride come in?

Mosapride is available in 6 different pack sizes.

Is Mosapride in stock?

Mosapride is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Mosapride?

Mosapride is manufactured by QuantiMol.

What is the estimated delivery time for Mosapride?

Estimated delivery time for Mosapride is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Mosapride?

The safety data sheet for Mosapride is available here: http://file.medchemexpress.com/batch_PDF/HY-B0189/Mosapride-SDS-MedChemExpress.pdf.

Mosapride

Mosapride is an orally active gastroenterokinetic compound. Mosapride is a 5HT4 agonist. Mosapride is a CYP inducer. Mosapride has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride can be used in the study of gastrointestinal diseases[1][2][3][4][5][6][7].

Product Specifications

CAS Number

112885-41-3

Product Name Alternative

TAK-370; AS-4370

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H332, H335

Target

5-HT Receptor; Cytochrome P450; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/mosapride.html

Purity

99.87

Solubility

DMSO : 66.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NCC1CN(CC2=CC=C(F)C=C2)CCO1)C3=CC(Cl)=C(N)C=C3OCC

Molecular Formula

C21H25ClFN3O3

Molecular Weight

421.89

Precautions

H302, H315, H319, H332, H335

References & Citations

[1]Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT (4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35 (7) :745-67.|[2]Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68 (7) :981-91.|[3]Kim HS, et al. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil. 2008 Feb;20 (2) :169-76.|[4]Kim YH, et al. Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay. Biomol Ther (Seoul) . 2015 Sep;23 (5) :486-92.|[5]Uchida M, et al. Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats. J Pharmacol Sci. 2013;121 (4) :282-7.|[6]Fujisawa M, et al. The 5-HT4 receptor agonist mosapride attenuates NSAID-induced gastric mucosal damage. J Gastroenterol. 2010 Feb;45 (2) :179-86.|[7]Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct;386 (10) :905-16.